A model of diabetic neuropathy caused by streptozotocin in rats has shown the neuroprotective properties of GLP-1RA semaglutide by reducing inflammation and oxidative stress by inhibiting the activity of astrocytes and microglia [32]
Its an every day challenge to convince employers that GLP-1 coverage benefits extend to their organizations, not just the individual patients, Hern said
PubMed Lau, A., Hnge, B.L., Jorsal, T., Kuhlmann, O., Vestergaard, P., & Vilsbll, T
According to the researchers, up to 85.1% of those treated with survodutide achieved at least a 5% reduction in their weight, contrasting with only 38.8% in the placebo group who reached this goal